NO20071718L - Anvendelse av A2B-adenosinreseptorantagonist til a lege sar - Google Patents

Anvendelse av A2B-adenosinreseptorantagonist til a lege sar

Info

Publication number
NO20071718L
NO20071718L NO20071718A NO20071718A NO20071718L NO 20071718 L NO20071718 L NO 20071718L NO 20071718 A NO20071718 A NO 20071718A NO 20071718 A NO20071718 A NO 20071718A NO 20071718 L NO20071718 L NO 20071718L
Authority
NO
Norway
Prior art keywords
adenosine receptor
receptor antagonist
ulcers
cure
cure ulcers
Prior art date
Application number
NO20071718A
Other languages
English (en)
Norwegian (no)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20071718L publication Critical patent/NO20071718L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO20071718A 2004-09-01 2007-03-30 Anvendelse av A2B-adenosinreseptorantagonist til a lege sar NO20071718L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20071718L true NO20071718L (no) 2007-03-30

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071718A NO20071718L (no) 2004-09-01 2007-03-30 Anvendelse av A2B-adenosinreseptorantagonist til a lege sar

Country Status (22)

Country Link
US (1) US20060058322A1 (ru)
EP (1) EP1789053B1 (ru)
JP (2) JP4929173B2 (ru)
KR (1) KR101247528B1 (ru)
CN (1) CN101043889B (ru)
AU (1) AU2005282860B2 (ru)
CA (1) CA2578702A1 (ru)
DK (1) DK1789053T3 (ru)
ES (1) ES2387653T3 (ru)
HK (1) HK1107261A1 (ru)
HR (1) HRP20120712T1 (ru)
IL (1) IL181634A (ru)
MX (1) MX2007002437A (ru)
NO (1) NO20071718L (ru)
NZ (1) NZ553487A (ru)
PL (1) PL1789053T3 (ru)
PT (1) PT1789053E (ru)
RS (1) RS52455B (ru)
RU (1) RU2385322C2 (ru)
SI (1) SI1789053T1 (ru)
WO (1) WO2006028810A2 (ru)
ZA (1) ZA200701777B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1658291T3 (pl) * 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
NZ554485A (en) 2004-10-15 2010-12-24 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
CA2718983C (en) * 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
IL277144B1 (en) * 2018-03-05 2024-02-01 Teon Therapeutics Inc Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
CA2400206A1 (en) * 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
RU2318824C2 (ru) * 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
JP4859666B2 (ja) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2006028810A3 (en) 2006-09-28
EP1789053B1 (en) 2012-06-13
AU2005282860B2 (en) 2012-03-22
HRP20120712T1 (hr) 2012-10-31
HK1107261A1 (en) 2008-04-03
ES2387653T3 (es) 2012-09-27
US20060058322A1 (en) 2006-03-16
RS52455B (en) 2013-02-28
PL1789053T3 (pl) 2012-12-31
JP2008511654A (ja) 2008-04-17
CA2578702A1 (en) 2006-03-16
NZ553487A (en) 2010-09-30
WO2006028810A2 (en) 2006-03-16
RU2385322C2 (ru) 2010-03-27
MX2007002437A (es) 2007-08-14
DK1789053T3 (da) 2012-08-06
KR101247528B1 (ko) 2013-04-15
IL181634A0 (en) 2007-07-04
SI1789053T1 (sl) 2012-09-28
ZA200701777B (en) 2008-09-25
CN101043889A (zh) 2007-09-26
IL181634A (en) 2015-05-31
EP1789053A2 (en) 2007-05-30
JP4929173B2 (ja) 2012-05-09
JP2011246492A (ja) 2011-12-08
KR20070047816A (ko) 2007-05-07
RU2007107605A (ru) 2008-09-10
PT1789053E (pt) 2012-08-09
AU2005282860A1 (en) 2006-03-16
CN101043889B (zh) 2010-11-03

Similar Documents

Publication Publication Date Title
NO20071718L (no) Anvendelse av A2B-adenosinreseptorantagonist til a lege sar
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
WO2003028641A3 (en) Mch receptor antagonists
NO20074002L (no) Androgen reseptor-modulatorforbindelser og fremgangsmater
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2007076260A3 (en) Farnesoid x receptor agonists
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
NO20092652L (no) Konstruert anti-TSLP-antistoff
EP2054411A4 (en) NOVEL COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2006010423A3 (en) Azaindole inhibitors of mtp and apob
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20090295L (no) Substituerte heteroarylderivater
EP1861358A4 (en) NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
DK1861403T3 (da) Hidtil ukendte imidazol[1,5-a]pyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder dem
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2004010929A3 (en) METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application